1. Antipyretic analgesic Nonsteroidal anti-inflammatory drugs Anton Kohút

3. Pain perception

7. Analgesics Salicylates- Aspirin Salicylates- Aspirin Paracetamol Paracetamol Other nonsteroidal antiinflammatory drugs (NSAIDs) Other nonsteroidal antiinflammatory drugs (NSAIDs) IV. Opioid analgesics IV. Opioid analgesics

8. Aspirin

9. Salicin from Willow Bark.

10. Biosynthesis of eicosanoids

11. COX1 and COX2

12. Mechanism of action of aspirine

13. Salicylates Drugs Acetylsalicylic acid (aspirin) Acetylsalicylic acid (aspirin) Diflunisal Diflunisal Methylsalicylate Methylsalicylate Sulfasalazine Sulfasalazine Sodium salicylate Sodium salicylate Pharmacological actions Analgetic Antipyretic Antiinflammatory Antiagregatory Anticancerogenic

14. Side effects of salicylates Gastrointestinal effects. Gastrointestinal effects. Hepatic and Renal Effects Hepatic and Renal Effects Neurological effects (high doses stimulation followed by depression. Neurological effects (high doses stimulation followed by depression. Acid-Base balance Acid-Base balance Respiration. Salicylates stimulate respiration Respiration. Salicylates stimulate respiration Uricosuric Effects. Low doses may decrease urate excretion. Large doses induce uricosuria. Uricosuric Effects. Low doses may decrease urate excretion. Large doses induce uricosuria. Small doses of salicylate can block the effects of probenecid and other uricosuric agents Small doses of salicylate can block the effects of probenecid and other uricosuric agents

15. Side effects of salicylates - cont. Oxidative phosphorylation - the uncoupling of oxidative phosphorylation Oxidative phosphorylation - the uncoupling of oxidative phosphorylation Carbohydrate metabolism- large doses hyperglycemia and glycosuria and deplete liver and muscle glycogen. Carbohydrate metabolism- large doses hyperglycemia and glycosuria and deplete liver and muscle glycogen. Nitrogen metabolism - in toxic doses cause a significant negative nitrogen balance. Nitrogen metabolism - in toxic doses cause a significant negative nitrogen balance. Fat metabolism - reduce lipogenesis Fat metabolism - reduce lipogenesis Endocrine effects- large doses of stimulate steroid secretion. Endocrine effects- large doses of stimulate steroid secretion. Pregnancy- uses for long periods - reduced weights of babies. Pregnancy- uses for long periods - reduced weights of babies.

16. Pharmacokinetics of salicylates Absorption after p.o. are absorbed rapidly, After oral administration, the nonionized salicylates are passively absorbed from the stomach and the small intestine.  Appreciable concentrations are found in plasma in less than 30 minutes; a peak value is reached in about 2 hours  Appreciable concentrations are found in plasma in less than 30 minutes; a peak value is reached in about 2 hours  Rectal absorption is slower than after p. o. and is incomplete and unreliable;  Rectal absorption is slower than after p. o. and is incomplete and unreliable;  Salicylic acid is rapidly absorbed from the intact skin, especially when applied in oily liniments or ointments.  Salicylic acid is rapidly absorbed from the intact skin, especially when applied in oily liniments or ointments.

17. Pharmacokinetics (cont.) Distribution - distributed throughout most body tissues and most transcellular fluids, primarily by pH- dependent passive processes, readily crosses the placental barrier and BBB (not diflunizal).  The volume of distribution 13 l;. at high doses, increases to about 35 l  80% to 90% of the salicylate is bound to plasma proteins.

19. Pharmacokinetics of salicylates (cont.) Elimination  The biotransformation takes place in many tissues, but particularly in the liver.  Are excreted in the urine as free salicylic acid (10%), salicyluric acid (75%), salicylic phenolic (10%) and acyl (5%) glucuronides, and gentisic acid (<1%).  Half-life for aspirin is 15 minutes; that for salicylates is 2 to 3 hours in low doses and about 12 hours at usual antiinflammatory doses

20. (according to Lippincott´s Pharmacology, 2006 Effect of dose on the half-life of aspirin Aspirin Aspirin (low dose) (high dose) 12 11 10 9 8 7 6 5 4 12 3 2 1 3 2 1 11 10 9 8 7 5 4 3 2 1 t 1/2 = 3 hours t 1/2 = 15 hours

21. Therapeutic uses: a. Antipyretics and analgesics: Aspirin, sodium salicylate, choline salicylate, choline magnesium salicylate - used as antipyretics and analgesics: - headache, arthralgia, myalgia, - in the treatment of gout, rheumatic fever, and rheumatoid arthritis. Note: Salicylates are the drugs of choice in the treatment of rheumatoid arthritis. b. Diflunisal, a derivate of salicylic acid, is not metabolized to salicylate - it cannot cause salicylism. Diflunisal is 3-4 times more potent than aspirin as an analgesic and an anti- inflammatory agent, but it does not have antipyretic properties. Note: Diflunisal does not enter the central nervous system (CNS) and therefore cannot relieve fever.

22. Cardiovascular applications: inhibition of platelet aggregation. Low doses of aspirin are used prophylactically to decrease the incidence of transient ischemic attack and unstable angina in men as well as that of coronary artery thrombosis. Aspirin also facilitates Aspirin also facilitates closure of the patent ductus arteriosus (PGE2 is responsible for keeping the ductus arteriosus open). d. Colon cancer: Chronic use of aspirin may reduce the incidence of colorectal cancer.

23. Therapeutic Uses of salicylates (dose depends on the wanted effect) Analgesia - headache, arthritis, dysmenorrhea, neuralgia, and myalgia. in the same doses and manner as for antipyresis Analgesia - headache, arthritis, dysmenorrhea, neuralgia, and myalgia. in the same doses and manner as for antipyresis Antipyretic- in the same doses and manner as for analgesia Antipyretic- in the same doses and manner as for analgesia Rheumatoid arthritis - 2 to 6 g daily), Rheumatoid arthritis - 2 to 6 g daily), Other uses - treatment or prophylaxis platelet hyperaggregability (dose of aspirin is 40 to 325 mg per day). Other uses - treatment or prophylaxis platelet hyperaggregability (dose of aspirin is 40 to 325 mg per day). Inflammatory Bowel Disease - mesalamine (5- amino-salicyclic acid) Inflammatory Bowel Disease - mesalamine (5- amino-salicyclic acid)

24. Aspirin Usual dose Effect 80 – 160 mg Antiplatelet 325 – 1000 mg Analgesic, antipyretic 325 mg – 6 grams Antiinflammatory, tinnitus 6 – 10 grams Respiratory alkalosis 10 – 20 grams Fever, dehydration, acidosis > 20 grams Shock, coma

25. (according to Lippincott´s Pharmacology, 2006 Dose-dependent effects of salicylate 0 10 50 100 150 Lethal Severe Mild Intoxication Anti-inflammatory Analgesic Antipyretic Antiplatelet Plasma concetration of salicylate (mg/dL) Gastric bleeding Impaired blood clotting Hypersensitivity reactions Tinnitus Central hyperventilation Vasomotor collapse; Coma; Dehydration

26. Preventive use of aspirine

28. Paracetamol (acetaminophen)

29. Paracetamol Pharmacological properties  analgesic and antipyretic effects  is only a weak inhibitor of COX.  no effects on platelets, or the excretion of uric acid. Pharmacokinetics  is rapidly and completely absorbed from the gastrointestinal tract.  peak concentration in plasma in 30 to 60 minutes, and the half-life in plasma is about 2 hours   After large doses of paracetamol, the metabolite (N- acetyl-benzoquinoneimine) is formed -and hepatic necrosis can result.

30. HNCOCH 3 Sulfate OH Glucuronide Paracetamol Cytochrome P-450 mixed function oxidase NCOCH 3 HNCOCH 3 Glutathione Nucleophilic hepatic cell proteins O OH Cell macro-molecules Cell death Mercapturic acid (nontoxic) Toxic intermediate Therapeutic doses Toxic doses (according to Lippincott´s Pharmacology, 2006 Metabolism of paracetamol

31. Paracetamol (cont.) Therapeutic Uses is a suitable substitute for aspirin for analgesic or antipyretic uses; is a suitable substitute for aspirin for analgesic or antipyretic uses; Toxic Effects  In therapeutic dosage is usually well tolerated.  acute overdosage ( 2-3 g) is a dose-dependent, potentially fatal hepatic necrosis. Renal tubular necrosis and hypoglycemic coma also may occur. Toxicity is potentiated by ethanol Toxicity is potentiated by ethanol  antidot - N-acetylcysteine.

32. Nonsteroidal antiinflammatory drugs NSAIDs Inflammation represents a series of homeostatic events that have evolved to aid in our survival in the face of pathogens and tissue injry. Inflammation represents a series of homeostatic events that have evolved to aid in our survival in the face of pathogens and tissue injry.

33. NSAIDs NSADS act as : 1. cytokine inhibitors ( IL-1, TNF, IL-8), antibodies or antibody fragments. Antagonists to various peptides that contribute to cytokine-mediated responses (e.g., substance P, bradykinin) also are in development. 1. cytokine inhibitors ( IL-1, TNF, IL-8), antibodies or antibody fragments. Antagonists to various peptides that contribute to cytokine-mediated responses (e.g., substance P, bradykinin) also are in development. 2. inhibitors of cell adhesion molecules (these include soluble fragments of receptors to bind cell adhesion molecules and use of antibodies, peptides, and carbohydrate moieties to block cell adhesion molecules. 2. inhibitors of cell adhesion molecules (these include soluble fragments of receptors to bind cell adhesion molecules and use of antibodies, peptides, and carbohydrate moieties to block cell adhesion molecules. 3. phospholipase A2 inhibitors - glucocorticoids but whose toxicity will be less frequent and severe than that of the steroids). 3. phospholipase A2 inhibitors - glucocorticoids but whose toxicity will be less frequent and severe than that of the steroids). 4. inhibitors of lipooxygenase and leukotriene receptors, 4. inhibitors of lipooxygenase and leukotriene receptors, 5. isoform specific inhibitors of cyclooxygenase (meloxicam). 5. isoform specific inhibitors of cyclooxygenase (meloxicam).

35. Classification of NSAIDs

37. Indomethacin Pharmacological properties  has prominent antinflammatory and analgesic-antipyretic properties, is more potent than aspirin.  effects of indomethacin are evident in patients with rheumatoid and other types of arthritis, including acute gout.  is evidence for both a central and a peripheral action; it also is an antipyretic.  is also inhibitor of polymorphonuclear leukocytes. Pharmacokinetics  After p. o. oral ingestion the peak concentration within 2 hours.  Its concentration in synovial fluid is equal to that in plasma within 5 hours.  Indomethacin is converted primarily to inactive metabolites, including those formed by O-demethylation (about 50%), conjugation with glucuronic acid (about 10%), and N-deacylation.  10% - 20% of the drug is excreted unchanged in the urine, in part by tubular secretion.  The half-life averages about 3 hours.

38. Indomethacin Therapeutic uses  Analgesic-antipyretics  Treatment of ankylosing spondylitis and osteoarthrosis, treatment of acute gout  in obstetrics and neonatal medicine. - as a tocolytic agent to suppress uterine contractions.  - cardiac failure in neonates caused by a patent ductus arteriosus Side effects about 20% must discontinue its use. Most adverse effects are dose-related.  GIT  some fatal cases of hepatitis and jaundice have been reported.  most frequent is severe frontal headache.  hematopoietic reactions include neutropenia, thrombocytopenia, and, rarely, aplastic anemia.

39. diclofenac, felbinac, ibuprofen, ketoprofen, piroxicam, naproxen, flurbiprofen and others.

40. Gout is a form of arthritis

41. Development of gout

45. Antirheumatic Drugs (drugs used to treat rheumatoid arthritis)

47. The major classes of antirheumatic drugs include: 1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs: ibuprofen naproxen indomethacin. 2. Corticosteroids: prednisone and dexamethasone.

48. Is classified as an auto-immune disease Is classified as an auto-immune disease Physicians now use Disease Modifying Anti- Rheumatic Drugs (DMARDs) and Slow-Acting Antirheumatic Drugs (SAARDs). Physicians now use Disease Modifying Anti- Rheumatic Drugs (DMARDs) and Slow-Acting Antirheumatic Drugs (SAARDs). The major classes of antirheumatic drugs include: 1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs: ibuprofen (Motrin, Nuprin or Advil), naproxen (Naprosyn, Aleve) indomethacin (Indocin). 2. Corticosteroids: prednisone and dexamethasone.

49. DMARDs influence the disease process itself and do not only treat symptoms DMARDs influence the disease process itself and do not only treat symptoms -Antimalarials DMARDs include chloroquine (Aralen) and hydroxychloroquine (Plaquenil). -Antimalarials DMARDs include chloroquine (Aralen) and hydroxychloroquine (Plaquenil). - Immunosuppresive cytotoxic drugs: methotrexate, mechlorethamine, cyclophosphamide, leflunomide, cyclosporine A, chlorambucil, and azathioprine. - Immunosuppresive cytotoxic drugs: methotrexate, mechlorethamine, cyclophosphamide, leflunomide, cyclosporine A, chlorambucil, and azathioprine. - Slow-Acting Antirheumatic Drugs (SAARDs): are a special class of DMARDs and the effect of these drugs is slow acting and not so quickly apparent as that of the NSAIDs. Example is aurothioglucose (gold salt). - Monoclonal antibody: etanercept, infliximab anti- TNFdrugs

50. - Anakinra (recombinant interleukin-1 receptor antagonist) Monoclonal antibody: anti-TNF drugs: etanercept, infliximab, leflunomide, Remicade anti-TNF drugs: Adalimumab, etanercept, infliximab, leflunomide, Remicade